Sylvant (siltuximab) 400?mg Vial Injection – For Research Use Only

Description

Siltuximab (CNTO 328) is a chimeric (human–mouse) IgG1? monoclonal antibody specifically targeting IL?6. It prevents IL?6 from activating its soluble and membrane-bound receptors, reducing B?cell proliferation, VEGF secretion, and inflammatory cascades. Although clinically approved for idiopathic multicentric Castleman’s disease, it is used in research as a tool to model IL?6–driven hyperinflammation, cytokine storm, and lymphoproliferative processes. Provided as a 400?mg vial for intravenous use. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Siltuximab neutralizes IL?6, a central cytokine in inflammatory and lymphoproliferative pathways. Its research utility spans modeling cytokine storms, IL?6–driven disease mechanisms, VEGF-associated vascular growth, and signal transduction in hyperinflammation. Useful for cytokine pharmacodynamics, immune modulation assays, and lymphoid proliferation studies. For laboratory research use only.

Side Effects (For Reference Only in Research Models)

Clinical analog data note possible adverse events such as weight gain, rash, pruritus, hyperuricemia, upper respiratory infection, hypertension, fatigue, neutropenia, and infusion reactions. These observations inform safety and toxicity design in research dosing models.

Disclaimer

Sylvant (siltuximab) is strictly intended for laboratory research use only. Not for human or veterinary therapeutic, diagnostic, or prophylactic use.